[治疗急性肌肉细胞白血病的方法和中国的贡献]
1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine at Shanghai, Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
全跨视网红酸 (ATRA) 和三氧化 (ATO) 已经改变了急性血清性白血病 (APL) 的治疗方法,使得生存率从不到35%提高到90%以上. 中国研究人员开创了这些向治疗方法,大大推进了APL的管理.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 从历史上来看,急性前列细胞白血病 (APL) 的早期死亡率很高.
- 向性癌症治疗已经彻底改变了APL治疗.
- 全跨网红酸 (ATRA) 和三氧化 (ATO) 是关键的治疗药物.
研究的目的:
- 审查APL中的关键治疗突破.
- 阐明APL治疗的科学机制和临床意义.
- 确定优化APL疾病管理的挑战.
主要方法:
- 开创ATRA诱导的差异化疗法.
- 验证ATO的临床疗效. 验证ATO的临床疗效.
- 克隆PML::RARA和PLZF::RARA融合基因.
- 建立协同的向治疗方案.
- 探索与ATRA结合的口服.
主要成果:
- ATRA和ATO显著改善了APL的预后,使5年生存率提高到90%以上.
- 一个协同的向治疗方案在临床试验中实现了95.7%的无疾病生存率.
- 口服和ATRA提供具有成本效益的APL治疗选择.
结论:
- 像ATRA和ATO这样的向疗法代表了APL治疗的里程碑.
- 中国研究人员为APL的治疗进展做出了重大贡献.
- 需要进一步的研究来优化APL管理和解决剩余的挑战.
更多相关视频
10:02Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
Published on: January 6, 2023
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
相关概念视频
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Differentiation of Common Myeloid Progenitor Cells
Targeted Cancer Therapies
There are several types of targeted therapies against...
